Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07220603
PHASE2

An Open-Label Extension Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1 (FREEDOM-OLE)

Sponsor: PepGen Inc

View on ClinicalTrials.gov

Summary

The purpose of this study is to learn about the long-term safety and tolerability of PGN-EDODM1 in participants with myotonic dystrophy type 1 (DM1) who have completed a prior study with PGN-EDODM1.

Official title: An Open-Label Extension Study Evaluating Safety and Pharmacokinetics in Participants With Myotonic Dystrophy Type 1 (FREEDOM-OLE)

Key Details

Gender

All

Age Range

Any - Any

Study Type

INTERVENTIONAL

Enrollment

48

Start Date

2025-12-23

Completion Date

2029-01

Last Updated

2026-03-30

Healthy Volunteers

No

Interventions

DRUG

PGN-EDODM1

Administered by intravenous (IV) infusion

Locations (3)

University of Calgary

Calgary, Alberta, Canada

Ottawa Hospital Research Institute

Ottawa, Ontario, Canada

CIUSSS du Saguenay-Lac-Saint-Jean

Saguenay, Canada